AIkido Pharma Inc (AIKI)

[postyle]

Hard to value pre-revenue PIPCOs that are at the early stages of their monetization campaigns.

The reality of SPEX, which I have commented on multiple times previously, is that the market did not understand the capital structure of the company due to the complex nature of the merger with North South.

When it was between $8 and $10 back in Sept., I wrote this was not the price range for long-term buy & hold investors to get in. I also wrote there would be a lot of selling and that the stock would be heavily shorted. The market cap at that time ($170 mm) was very lofty for a patent assertion company with no revenues and lack of clarity in its revenue opportunities.

Keep in mind the financial portals still misrepresent the number of shares outstanding. So expect volatility as the story is still widely misunderstood.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91919311
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92057383
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92057875